Modulation of the sublingual microenvironment and pH-dependent transport pathways to enhance atropine sulfate permeability for the treatment of organophosphates poisoning.


Journal

International journal of pharmaceutics
ISSN: 1873-3476
Titre abrégé: Int J Pharm
Pays: Netherlands
ID NLM: 7804127

Informations de publication

Date de publication:
05 Sep 2021
Historique:
received: 11 05 2021
revised: 14 07 2021
accepted: 15 07 2021
pubmed: 27 7 2021
medline: 8 9 2021
entrez: 26 7 2021
Statut: ppublish

Résumé

Atropine sulfate (AS) auto-injectors are the only approved antidote for out-of-hospital emergency treatment of organophosphates (OP) toxicity. However, they are only available for military use and require the administration of multiple auto-injectors. Therefore, an alternative, patient-friendly and more affordable fast-disintegrating sublingual tablets (FDSTs) of AS were previously developed. In this article, the effect of modifying the microenvironment's pH and/or using penetration enhancers on AS sublingual transport pathways were evaluated in an attempt to further enhance AS sublingual permeability. Ten different AS FDST formulations with or without the incorporation of alkalizer and various penetration enhancers were manufactured and characterized. AS permeability was investigated through excised porcine sublingual membrane using Franz cells. Results showed that the incorporation of either a transcellular enhancer or alkalizer achieved a significantly higher AS permeability enhancement (twofold). Combining sodium bicarbonate (Na Bicarb) 2% as alkalizer with sodium dodecyl sulfate (SDS) 1% as a transcellular enhancer resulted in the greatest synergistic enhancement in AS sublingual permeability (up to twelvefold). In conclusion, the modified AS FDST developed in this work has the potential to improve the pharmacokinetic parameters of AS following sublingual administration for the first-aid treatment of OP toxicity in future animal bioequivalency studies.

Identifiants

pubmed: 34310952
pii: S0378-5173(21)00704-3
doi: 10.1016/j.ijpharm.2021.120898
pii:
doi:

Substances chimiques

Organophosphates 0
Tablets 0
Atropine 7C0697DR9I

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

120898

Informations de copyright

Copyright © 2021 Elsevier B.V. All rights reserved.

Auteurs

Mutasem Rawas-Qalaji (M)

College of Pharmacy, University of Sharjah, Sharjah 27272, United Arab Emirates; Research Institute of Medical and Health Sciences, University of Sharjah, Sharjah 27272, United Arab Emirates; Dr. Kiran C. Patel College of Allopathic Medicine, Nova Southeastern University, Fort Lauderdale, FL 33326, USA. Electronic address: mqalaji@sharjah.ac.ae.

Rawan Bafail (R)

College of Pharmacy, Taibah University, Medina, Saudi Arabia.

Iman Saad Ahmed (IS)

College of Pharmacy, University of Sharjah, Sharjah 27272, United Arab Emirates; Research Institute of Medical and Health Sciences, University of Sharjah, Sharjah 27272, United Arab Emirates.

Mohammad Nasir Uddin (MN)

College of Pharmacy, Mercer University, Atlanta, GA 30341, USA.

Sami Nazzal (S)

School of Pharmacy, Texas Tech University Health Sciences Center, Dallas, TX 75235, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH